

ALLIED HEALTHCARE PRODUCTS INC

Form 8-K

August 30, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

August 24, 2017

**ALLIED HEALTHCARE PRODUCTS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**0-19266**

**25-1370721**

(State or Other Jurisdiction (Commission (IRS Employer  
of Incorporation) File Number) Identification No.)

**1720 Sublette Avenue, St. Louis, Missouri 63110**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code

**(314) 771-2400**

Not applicable

(Former name or former address, if changed since last report)

Edgar Filing: ALLIED HEALTHCARE PRODUCTS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**(e) Increases in Base Compensation of Certain Named Executive Officers**

On August 24, 2017, the Compensation Committee of the Board of Directors of Allied Healthcare Products, Inc. (the “Company”) approved the following increases in the base salary of the named executive officers listed below:

- (i) Daniel C. Dunn, Vice President – Finance and Chief Financial Officer, received an increase of \$10,000 per year, to a new base salary of \$226,000; and
- (ii) Andrew D. Riley, Vice President – Operations, received an increase of \$30,000 per year, to a new base salary of \$225,000.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ALLIED  
HEALTHCARE  
PRODUCTS, INC.

Date: August 30, 2017 By: /s/ Daniel C. Dunn  
Daniel C. Dunn  
Chief Financial  
Officer